Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rel-Cisapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | HMGCR | P04035 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cisapride SCHEMBL5053853 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL29389140 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL16132 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Cisapride SCHEMBL16131 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL7854542 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL1759279 | 1.00 | HTR4 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL8211188 | 0.99 | HTR4 (0.98) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Cisapride SCHEMBL8211180 | 0.99 | HTR4 (0.98) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Rel-Cisapride SCHEMBL9721799 | 0.99 | KCNH2 (1.00) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Cisapride SCHEMBL9074812 | 0.99 | HTR4 (0.98) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4590681-A1 | CARDIOPROTECTIVE LIPID AND METHOD OF USE | Signpath Pharma, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| EP-4580632-A2 | METHODS OF USING ITRACONAZOLE DRY POWDERS | Pulmatrix Operating Company, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | claimed |
| WO-1995001803-A1 | H2 ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | claimed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | claimed |
| EP-0632720-A1 | ALKYL-SUBSTITUTED CELLULOSE-BASED SUSTAINED-RELEASE ORAL DRUG DOSAGE FORMS | DEPOMED SYSTEMS, INC. (US) | 1995-01-11 | — | — | EP | claimed |
| WO-1995000478-A1 | ARYLTRIFLATES AND RELATED COMPOUNDS | LUNDBECK & CO AS H (DK) | 1995-01-05 | — | — | WO | claimed |
| EP-0617620-A1 | USE OF 5-HT4 MODULATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF THE BLADDER DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1994-10-05 | — | — | EP | claimed |
| WO-1994001112-A1 | METHODS OF USING (-) CISAPRIDE FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE AND OTHER DISORDERS | SEPRACOR INC. (US) | 1994-01-20 | — | — | WO | claimed |
| WO-1994001111-A1 | METHODS OF USING (+) CISAPRIDE FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE AND OTHER DISORDERS | SEPRACOR INC. (US) | 1994-01-20 | — | — | WO | claimed |
| WO-1993018755-A1 | ALKYL-SUBSTITUTED CELLULOSE-BASED SUSTAINED-RELEASE ORAL DRUG DOSAGE FORMS | DEPOMED SYSTEMS, INCORPORATED (US) | 1993-09-30 | — | — | WO | claimed |
| WO-1993012785-A1 | USE OF 5-HT4 MODULATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF THE BLADDER DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1993-07-08 | — | — | WO | claimed |
| US-4355986-A | Outboard motor with elevated horizontal pivot axis | OUTBOARD MARINE CORPORATION (US) | 1982-10-26 | — | — | US | claimed |